Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. According to GlobalData, Phase III drugs for Parkinson’s Disease have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Pharmaceutical 40

Pharmaceutical 40

pharmaphorum

JULY 15, 2022

Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson’s disease candidate KW-6356, a drug in the adenosine A2A receptor antagonist class. The post Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s appeared first on.

Competition 59

Competition Marketing Medicine FDA 59

Pharmaceutical Technology

JUNE 9, 2023

MBF-015is under clinical development by Medibiofarma and currently in Phase I for Parkinson's Disease.

40

40

pharmaphorum

OCTOBER 31, 2022

VRG50635 was discovered using Verge’s AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using data on DNA, RNA and protein profiles to identify new targets and drug that can interact with them. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.

Pharma 124

Pharma Leads Medicine Marketing 124

European Pharmaceutical Review

MAY 16, 2023

1 Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic 1 as advanced therapy medicinal products (ATMPs). in a 2023 paper published in the Journal of Clinical Microbiology. Parkinson’s occurs when an area of the brain loses dopamine-producing nerve cells.

Manufacturing 86

Manufacturing Medicine Marketing Medical 86

Pharmaceutical Technology

JUNE 2, 2023

The drug candidate has completed a Phase IIa and Phase IIb/III clinical trial for Alzheimer’s disease, a Phase II and a Phase III trial in Rett syndrome adult patients, and a Phase II proof-of-concept trial in Parkinson’s disease.

Pharmaceutical 52

Pharmaceutical Patients 52

European Pharmaceutical Review

OCTOBER 17, 2022

and Parkinson’s UK’s drug development and discovery division, Parkinson’s Virtual Biotech , will collaborate on a new Phase II trial to study the effects of the drug ENT-01 on Parkinson’s Disease (PD)-associated dementia. . US biopharma company Enterin Inc. The drug ENT-01 helps to inhibit ?

Biopharma 90

Biopharma Patients Pharmaceutical Marketing 90

pharmaphorum

JANUARY 26, 2023

Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring. ” The post Roche, Boehringer tap biosensor firms for patient studies appeared first on.

Patients 68

Patients Healthcare Healthcare Pharma 68

Legacy MEDSearch

JUNE 15, 2023

Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.

Patients 98

Patients Recruitment Pharmacology Side effects 98

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 9% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Pharmaceutical 40

Pharmaceutical 40

pharmaphorum

AUGUST 30, 2022

The Cardiff-based company’s pipeline also includes an oral testosterone in clinical trials for hypogonadism, as well as a modified-release levothyroxine for hypothyroidism and oligonucleotide-based therapy for Cushing’s disease in preclinical development. In July, Diurnal reported product sales of around £2.3

Sales 86

Sales Physicians Leads Patients 86

Pharma Marketing Network

MARCH 2, 2022

” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. Neurology’s research is mostly concentrated on Alzheimer’s and Parkinson’s disease.

52

52

pharmaphorum

JANUARY 3, 2023

. “The data comparing the impact of evenamide at six weeks versus six months, reported today, suggests that not only was there sustained improvement in the key measures, but the proportion of patients achieving clinically meaningful improvement increased over time,” he explained.

Side effects 102

Side effects Biopharma Patients Competition 102

Pharma Marketing Network

MARCH 2, 2022

” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. Neurology’s research is mostly concentrated on Alzheimer’s and Parkinson’s disease.

Networking 52

Networking Pharma Marketing 52

pharmaphorum

DECEMBER 16, 2022

Sio Gene Therapies’ litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the ‘vant’ companies originally founded by entrepreneur Vivek Ramaswamy.

Distribution 59

Distribution Pharma 59

European Pharmaceutical Review

DECEMBER 19, 2022

Neuromuscular diseases (NMDs) are a broad group of conditions in which pathologies affect the peripheral nervous system (PNS), the neuromuscular junction or skeletal muscle. ALS is a progressive neurodegenerative disease that affects motor neurons within the brain and spinal cord, resulting in muscle weakness, disability and eventually death.

Patients 82

Patients Recruitment Pharmaceutical Leads 82

European Pharmaceutical Review

OCTOBER 5, 2023

The field of gene therapy has witnessed remarkable advancements; it has evolved from being an exceedingly complex solution to a viable option for addressing rare diseases. Our next challenge lies in the scalable application of gene therapy for pathway diseases like Parkinson’s. This is its present application.

Manufacturing 86

Manufacturing Consulting Patients Marketing 86

Legacy MEDSearch

JULY 6, 2023

The system delivers an intervention based on the principle of Rhythmic Auditory Stimulation (RAS), a well-researched clinical intervention utilizing the mechanism of auditory-motor entrainment, through which the motor and auditory systems in the brain subconsciously synchronize to an external cue, such as music.

FDA 52

FDA Food and Drug Administration Recruitment Medical 52

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

FDA 52

FDA Marketing Pharma Sales 52

Legacy MEDSearch

OCTOBER 25, 2022

Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs. We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search.

Marketing 52

Marketing FDA Food and Drug Administration Recruitment 52

MedCity News

APRIL 18, 2024

Cerevel Therapeutics drug tavapadon met the main and secondary goals of a pivotal Parkinson’s disease clinical trial. The post Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand appeared first on MedCity News.

Biopharma 114

Biopharma Pharma 114

Pharmaceutical Technology

OCTOBER 18, 2022

A new study identifies a novel cerebrospinal fluid biomarker for Parkinson’s disease, expanding the scope of possible drug targets. There is potential that these structural changes could allow for a new method of differentiating different disease subtypes, thus expanding the scope for new PD therapeutics.

Patients 105

Patients Pharmaceutical Networking Medicine 105

MedCity News

JUNE 14, 2023

Cala Health recently launched its kIQ system — which it calls the first noninvasive wearable device cleared by the FDA to temporarily relieve tremors in people with essential tremor and Parkinson’s disease.

FDA 98

FDA Medical 98

MedCity News

AUGUST 28, 2023

A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.

Pharmaceutical 107

Pharmaceutical Biopharma Pharma 107

MedCity News

FEBRUARY 28, 2023

An Aptinyx Parkinson’s disease drug candidate failed to beat a placebo—the biotech’s third mid-stage failure in the past year. Aptinyx is now terminating a separate PTSD program, cutting costs, and exploring “strategic alternatives.”

Biopharma 98

Biopharma Pharma 98

PM360

SEPTEMBER 7, 2023

Mason learned that lesson while working with argenx to launch VYVGART (efgartigimod alfa-fcab), the first FDA-approved treatment of its kind for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disease. Throughout the experience, patients follow along through an interactive workbook.

Patients 105

Patients Pharma Education Doctors 105

pharmaphorum

JULY 13, 2022

Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people worldwide, and their prevalence is only increasing, according to the World Health Organization. Utilising new digital technology, it turns out there are a number of ways to introduce objective measurement into the world of neurodegenerative diseases.

Recruitment 94

Recruitment Pharma Patients Management 94

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. The buyout – for $12.50 For Akouos shareholders, Lilly’s offer comes with a CVR split into three, valued at $1 apiece.

Medicine 52

Medicine FDA Patients Pharma 52

Cadensee

OCTOBER 19, 2021

It's a rare genetic disease that infects the development of the autonomic nervous system, which controls everything we take for granted. I can tell you nowadays that we are building a clinical pipeline, of course for several other indications. And again, we have the clinical community working closely with the US. Every single.

Patients 52

Patients Medical Networking Marketing 52